Follow Denali Therapeutics to never miss an important update.
Denali reported its first ever product revenue this quarter, earning about 3.6 million dollars from its new drug, Avlayah. While the company lost 68 cents per share, which was more than the 51 cents analysts expected, the focus for a young biotech firm is on the start of its commercial business rather than short-term losses. Denali also boosted its cash pile to over 1.1 billion dollars by selling a Priority Review Voucher, a special credit from the government that speeds up the drug approval process.
This is a critical moment because it proves the company can successfully turn its lab research into a real product. The drug uses a delivery system designed to cross the blood-brain barrier, a protective layer that usually keeps medicines out of the brain. If this launch continues to go well, it suggests the same delivery technology could work for the company's other experimental drugs for Alzheimer's and Parkinson's diseases.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Denali reported its first full quarter of sales for Avlayah, a treatment for a rare genetic disorder called Hunter syndrome. The drug brought in $3.6 million in its first few months on the market. While this is a small number today, it is a major milestone because it proves the company can successfully turn its lab research into a commercial product.
The company also strengthened its finances by selling a Priority Review Voucher for $195 million. These vouchers are special credits the government gives to companies that develop drugs for rare diseases, which can be sold to other firms to speed up their own drug approvals. This sale helped boost Denali's cash to over $1.1 billion, giving it a long runway to fund its other expensive trials for Alzheimer's and Parkinson's diseases.
Source: GlobeNewsWire
The company reported the completion of an asset deal in a recent regulatory filing. While the filing confirms the transaction is finished, it did not immediately share the specific price or the name of the assets involved.
For a biotechnology firm like this, these moves usually involve buying new drug candidates to fill the pipeline or selling off older research to focus on its main projects. We will look for more details on how this affects its cash levels in the upcoming quarterly report.
Source: 8-K filing
Morgan Stanley raised its price target from $35 to $36 while keeping an overweight rating, which means they expect the stock to perform better than the broader market. This small nudge upward suggests the firm remains confident in the company's transition from a research-focused lab to a commercial business with its first drug now on the market.
Source: Morgan Stanley
Wedbush analysts raised their price target from $20 to $26, a 30 percent increase. This move reflects growing optimism about the company's ability to get its brain-disease treatments through the final stages of testing and into the hands of patients.
Even with the higher target, the stock still trades below this level. This suggests that while analysts are becoming more positive, they are still waiting for more data from the ongoing commercial launch of its first drug before calling for a much higher valuation.
Source: Wedbush
The company has a habit of beating expectations, clearing the bar in five of the last eight quarters as it moved toward its first commercial launch.
| Expectation | |
|---|---|
| EPS | $-0.41 |
| Revenue | $12M |
Follow Denali Therapeutics to get the latest and most important updates.
Follow DNLI